Singapore's S*BIO Initiates Phase II Trials In Canada; Picks Up New Investor
This article was originally published in PharmAsia News
Executive Summary
Singapore-based biotech company S*BIO announced it has initiated Phase II trials of its oral histone deacetylase (HDAC) inhibitor SB939 in prostate cancer
You may also be interested in...
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison
Japanese Firm Mitsui Invests In China's Hutchison MediPharma; First Step Toward An IPO?
SHANGHAI - Hutchison MediPharma, one of China's leading biotechs, announced Nov. 8 that Tokyo-based venture capital firm Mitsui had acquired a 12.2 percent stake in the company for $12.5 million, generating speculation among China watchers that it could be a first step toward self-funding and an eventual IPO for Hutchison
Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors
PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4